Lead sponsor
Banner Health
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
1
Ongoing
260
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2/3
2
Trials by status
Not yet recruiting
1
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Diseasemild AD dementia · PSEN1 mutation requiredPh 2/3Not yet recruiting240
Thalidomide for Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2/3Unknown20